Canada Markets open in 46 mins

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
7.45-0.15 (-1.97%)
At close: 03:01PM EDT
Full screen
Previous Close7.60
Open7.60
Bid7.55 x 0
Ask7.73 x 0
Day's Range7.40 - 7.60
52 Week Range6.00 - 13.80
Volume1,299
Avg. Volume5,209
Market Cap3.216B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.50
  • GlobeNewswire

    ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022. “Q2 was another quarter of strong pro

  • Simply Wall St.

    Can ProMIS Neurosciences (TSE:PMN) Afford To Invest In Growth?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • GlobeNewswire

    ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

    Poster presentation of study highlighting oligomer selectivity of PMN310 compared to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster pr